|
1
|
Wong D, Kea B, Pesich R, Higgs BW, Zhu W,
Brown P, Yao Y and Fiorentino D: Interferon and biologic signatures
in dermatomyositis skin: Specificity and heterogeneity across
diseases. PLoS One. 7:e291612012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bendewald MJ, Wetter DA, Li X and Davis
MD: Incidence of dermatomyositis and clinically amyopathic
dermatomyositis: A population-based study in Olmsted County,
Minnesota. Arch Dermatol. 146:26–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mantegazza R, Bernasconi P, Confalonieri P
and Cornelio F: Inflammatory myopathies and systemic disorders: A
review of immunopathogenetic mechanisms and clinical features. J
Neurol. 244:277–287. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nickoloff BJ and Nestle FO:
Dermatomyositis. Dermatologic Immunity Curr Dir Autoimmun. 10.
Karger AG; Basel: pp. 313–332. 2008, View Article : Google Scholar
|
|
5
|
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala
E, Mellemkjaer L, Airio A, Evans SR and Felson DT: Frequency of
specific cancer types in dermatomyositis and polymyositis: A
population-based study. Lancet. 357:96–100. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Antiga E, Kretz CC, Klembt R, Massi D,
Ruland V, Stumpf C, Baroni G, Hartmann M, Hartschuh W, Volpi W, et
al: Characterization of regulatory T cells in patients with
dermatomyositis. J Autoimmun. 35:342–350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reed AM and Ytterberg SR: Genetic and
environmental risk factors for idiopathic inflammatory myopathies.
Rheum Dis Clin North Am. 28:891–916. 2002. View Article : Google Scholar
|
|
8
|
Rothwell S, Cooper RG, Lamb JA and Chinoy
H: Entering a new phase of immunogenetics in the idiopathic
inflammatory myopathies. Curr Opin Rheumatol. 25:735–741. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dalakas MC: Muscle biopsy findings in
inflammatory myopathies. Rheum Dis Clin North Am. 28:779–798. 2002.
View Article : Google Scholar
|
|
10
|
Hornung T and Wenzel J: Innate
immune-response mechanisms in dermatomyositis: An update on
pathogenesis, diagnosis and treatment. Drugs. 74:981–998. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Greenberg SA: Sustained autoimmune
mechanisms in dermatomyositis. J Pathol. 233:215–216. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suárez-Calvet X, Gallardo E, Nogales-Gadea
G, Querol L, Navas M, Díaz-Manera J, Rojas-Garcia R and Illa I:
Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J
Pathol. 233:258–268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Diboun I, Wernisch L, Orengo CA and
Koltzenburg M: Microarray analysis after RNA amplification can
detect pronounced differences in gene expression using limma. BMC
Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bindea G, Mlecnik B, Hackl H, Charoentong
P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and
Galon J: ClueGO: A Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks.
Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
von Mering C, Huynen M, Jaeggi D, Schmidt
S, Bork P and Snel B: STRING: A database of predicted functional
associations between proteins. Nucleic Acids Res. 31:258–261. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamb J, Crawford ED, Peck D, Modell JW,
Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et
al: The Connectivity Map: Using gene-expression signatures to
connect small molecules, genes, and disease. Science.
313:1929–1935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baechler EC, Bauer JW, Slattery CA,
Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK,
Behrens TW and Reed AM: An interferon signature in the peripheral
blood of dermatomyositis subjects is associated with disease
activity. Mol Med. 13:59–68. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kao L, Chung L and Fiorentino DF:
Pathogenesis of dermatomyositis: Role of cytokines and interferon.
Curr Rheumatol Rep. 13:225–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Greenberg SA: A gene expression approach
to study perturbed pathways in myositis. Curr Opin Rheumatol.
19:536–541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener
PA, Pinkus JL, Beggs AH, Amato AA and Greenberg SA: Type I
interferon-inducible gene expression in blood is present and
reflects disease activity in dermatomyositis and polymyositis.
Arthritis Rheum. 56:3784–3792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hall JC and Rosen A: Type I interferons:
Crucial participants in disease amplification in autoimmunity. Nat
Rev Rheumatol. 6:40–49. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Salajegheh M, Kong SW, Pinkus JL, Walsh
RJ, Liao A, Nazareno R, Amato AA, Krastins B, Morehouse C, Higgs
BW, et al: Interferon-stimulated gene 15 (ISG15) conjugates
proteins in dermatomyositis muscle with perifascicular atrophy. Ann
Neurol. 67:53–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Härtlova A, Erttmann SF, Raffi FA, Schmalz
AM, Resch U, Anugula S, Lienenklaus S, Nilsson LM, Kröger A,
Nilsson JA, et al: DNA damage primes the type I interferon system
via the cytosolic DNA sensor STING to promote anti-microbial innate
immunity. Immunity. 42:332–343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marques RE, Guabiraba R, Russo RC and
Teixeira MM: Targeting CCL5 in inflammation. Expert Opin Ther
Targets. 17:1439–1460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bilgic H, Ytterberg SR, Amin S, McNallan
KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson
EJ, et al: Interleukin-6 and type I interferon-regulated genes and
chemokines mark disease activity in dermatomyositis. Arthritis
Rheum. 60:3436–3446. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Crescioli C, Sottili M, Bonini P, Cosmi L,
Chiarugi P, Romagnani P, Vannelli GB, Colletti M, Isidori AM, Serio
M, et al: Inflammatory response in human skeletal muscle cells:
CXCL10 as a potential therapeutic target. Eur J Cell Biol.
91:139–149. 2012. View Article : Google Scholar
|
|
28
|
Kim J, Choi JY, Park SH, Yang SH, Park JA,
Shin K, Lee EY, Kawachi H, Kohsaka H and Song YW: Therapeutic
effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C
protein-induced myositis mouse. Arthritis Res Ther. 16:R1262014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tournadre A, Lenief V, Eljaafari A and
Miossec P: Immature muscle precursors are a source of interferon-β
in myositis: Role of Toll-like receptor 3 activation and
contribution to HLA class I up-regulation. Arthritis Rheum.
64:533–541. 2012. View Article : Google Scholar
|
|
30
|
Cappelletti C, Baggi F, Zolezzi F,
Biancolini D, Beretta O, Severa M, Coccia EM, Confalonieri P,
Morandi L, Mora M, et al: Type I interferon and Toll-like receptor
expression characterizes inflammatory myopathies. Neurology.
76:2079–2088. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L, Dai T, Lv J, Ji K, Liu J, Zhang B
and Yan C: Role of Toll-like receptors and retinoic acid inducible
gene I in endogenous production of type I interferon in
dermatomyositis. J Neuroimmunol. 285:161–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sato S, Hoshino K, Satoh T, Fujita T,
Kawakami Y, Fujita T and Kuwana M: RNA helicase encoded by melanoma
differentiation-associated gene 5 is a major autoantigen in
patients with clinically amyopathic dermatomyositis: Association
with rapidly progressive interstitial lung disease. Arthritis
Rheum. 60:2193–2200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu X, Peng Q and Wang G: Discovery of new
biomarkers of idiopathic inflammatory myopathy. Clin Chim Acta.
444:117–125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Langfelder P, Mischel PS and Horvath S:
When is hub gene selection better than standard meta-analysis? PloS
One. 8:e615052013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
D'Cunha J, Knight E Jr, Haas AL, Truitt RL
and Borden EC: Immunoregulatory properties of ISG15, an
interferon-induced cytokine. Proc Natl Acad Sci USA. 93:211–215.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao C, Denison C, Huibregtse JM, Gygi S
and Krug RM: Human ISG15 conjugation targets both IFN-induced and
constitutively expressed proteins functioning in diverse cellular
pathways. Proc Natl Acad Sci USA. 102:10200–10205. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arshanapalli A, Shah M, Veerula V and
Somani AK: The role of type I interferons and other cytokines in
dermatomyositis. Cytokine. 73:319–325. 2015. View Article : Google Scholar
|
|
38
|
O'Connor KA, Abbott KA, Sabin B, Kuroda M
and Pachman LM: MxA gene expression in juvenile dermatomyositis
peripheral blood mononuclear cells: Association with muscle
involvement. Clin Immunol. 120:319–325. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Salaroli R, Baldin E, Papa V, Rinaldi R,
Tarantino L, De Giorgi LB, Fusconi M, Malavolta N, Meliconi R,
D'Alessandro R and Cenacchi G: Validity of internal expression of
the major histocompatibility complex class I in the diagnosis of
inflammatory myopathies. J Clin Pathol. 65:14–19. 2012. View Article : Google Scholar
|
|
40
|
van der Pas J, Hengstman GJ, ter Laak HJ,
Borm GF and van Engelen BG: Diagnostic value of MHC class I
staining in idiopathic inflammatory myopathies. J Neurol Neurosurg
Psychiatry. 75:136–139. 2004.PubMed/NCBI
|
|
41
|
Choi UY, Kang JS, Hwang YS and Kim YJ:
Oligoadenylate synthase-like (OASL) proteins: Dual functions and
associations with diseases. Exp Mol Med. 47:e1442015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sanayama Y, Ikeda K, Saito Y, Kagami S,
Yamagata M, Furuta S, Kashiwakuma D, Iwamoto I, Umibe T, Nawata Y,
et al: Prediction of therapeutic responses to tocilizumab in
patients with rheumatoid arthritis: Biomarkers identified by
analysis of gene expressionin peripheral blood mononuclear cells
using genome-wide DNA microarray. Arthritis Rheumatol.
66:1421–1431. 2014. View Article : Google Scholar : PubMed/NCBI
|
